Tip 112: RSV immunisation

Palivizumab (Synergis) is a humanized monoclonal antibody and provides passive immunity against RSV. It reduces hospitalisation rates and serious complications amongst high risk children. These are:

  • Less than 35 weeks gestation and under 6 months old at onset of RSV season
  • Under 2 years old on treatment for chronic lung disease
  • Under 2 years old with haemodynamically significant heart disease

Reference: Public Health England and the Department of Health. Immunisation against infectious disease. The Green Book; 2013: Chapter 27a v2.0, last updated 04/09/15. Crown Copyright.

Previously published: 21/05/14, 12/05/15

This entry was posted in Infection. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.